229 related articles for article (PubMed ID: 33547395)
1. NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.
Yoshihama S; Cho SX; Yeung J; Pan X; Lizee G; Konganti K; Johnson VE; Kobayashi KS
Sci Rep; 2021 Feb; 11(1):3258. PubMed ID: 33547395
[TBL] [Abstract][Full Text] [Related]
2. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
[TBL] [Abstract][Full Text] [Related]
4. NLRC5/CITA: A Key Player in Cancer Immune Surveillance.
Yoshihama S; Vijayan S; Sidiq T; Kobayashi KS
Trends Cancer; 2017 Jan; 3(1):28-38. PubMed ID: 28718425
[TBL] [Abstract][Full Text] [Related]
5. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
6. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
7. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
Sheng Y; Tong L; Geyu L
Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
[TBL] [Abstract][Full Text] [Related]
8. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
Rodig SJ; Gusenleitner D; Jackson DG; Gjini E; Giobbie-Hurder A; Jin C; Chang H; Lovitch SB; Horak C; Weber JS; Weirather JL; Wolchok JD; Postow MA; Pavlick AC; Chesney J; Hodi FS
Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021886
[TBL] [Abstract][Full Text] [Related]
9. Targeted demethylation and activation of
Sun X; Watanabe T; Oda Y; Shen W; Ahmad A; Ouda R; de Figueiredo P; Kitamura H; Tanaka S; Kobayashi KS
Proc Natl Acad Sci U S A; 2024 Feb; 121(6):e2310821121. PubMed ID: 38300873
[TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
11. G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma.
Kelly GM; Al-Ejeh F; McCuaig R; Casciello F; Ahmad Kamal N; Ferguson B; Pritchard AL; Ali S; Silva IP; Wilmott JS; Long GV; Scolyer RA; Rao S; Hayward NK; Gannon F; Lee JS
Clin Cancer Res; 2021 May; 27(9):2624-2635. PubMed ID: 33589432
[TBL] [Abstract][Full Text] [Related]
12. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.
Olbryt M; Rajczykowski M; Widłak W
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517213
[TBL] [Abstract][Full Text] [Related]
13. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
Vijayan S; Sidiq T; Yousuf S; van den Elsen PJ; Kobayashi KS
Immunogenetics; 2019 Mar; 71(3):273-282. PubMed ID: 30706093
[TBL] [Abstract][Full Text] [Related]
14. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
15. CITA/NLRC5: A critical transcriptional regulator of MHC class I gene expression.
Downs I; Vijayan S; Sidiq T; Kobayashi KS
Biofactors; 2016 Jul; 42(4):349-57. PubMed ID: 27087581
[TBL] [Abstract][Full Text] [Related]
16. Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy.
Miao YR; Liu CJ; Hu H; Yang M; Guo AY
Cells; 2022 Sep; 11(18):. PubMed ID: 36139377
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in melanoma.
Carlino MS; Larkin J; Long GV
Lancet; 2021 Sep; 398(10304):1002-1014. PubMed ID: 34509219
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma.
Lv L; Wei Q; Wang Z; Zhao Y; Chen N; Yi Q
Front Bioeng Biotechnol; 2021; 9():690186. PubMed ID: 34307322
[TBL] [Abstract][Full Text] [Related]
19.
Parakh S; Musafer A; Paessler S; Witkowski T; Suen CSNLW; Tutuka CSA; Carlino MS; Menzies AM; Scolyer RA; Cebon J; Dobrovic A; Long GV; Klein O; Behren A
Front Immunol; 2021; 12():672521. PubMed ID: 34177913
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic control of
Wang MM; Koskela SA; Mehmood A; Langguth M; Maranou E; Figueiredo CR
Front Immunol; 2023; 14():1152228. PubMed ID: 37077920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]